[1]王 芳 ),吴 歌 ),张珊珊),等.多发性骨髓瘤合并肾损害患者临床及病理特征分析[J].郑州大学学报(医学版),2019,(04):631-634.[doi:10.13705/j.issn.1671-6825.2018.09.136]
 WANG Fang),WU Ge),ZHANG Shanshan),et al.Clinical and pathological features of patients with multiple myeloma complicated with renal impairment[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(04):631-634.[doi:10.13705/j.issn.1671-6825.2018.09.136]
点击复制

多发性骨髓瘤合并肾损害患者临床及病理特征分析()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2019年04期
页码:
631-634
栏目:
应用研究
出版日期:
2019-07-20

文章信息/Info

Title:
Clinical and pathological features of patients with multiple myeloma complicated with renal impairment
作者:
王 芳1 )吴 歌2 ) 张珊珊2)姜中兴1 )田文亮1 )谢新生1 )曹伟杰1 )
1)郑州大学第一附属医院血液内科 郑州 450052;2)郑州大学第一附属医院肾脏内科 郑州 450052
Author(s):
WANG Fang1)WU Ge2)ZHANG Shanshan2)JIANG Zhongxing1)TIAN Wenliang1)XIE Xinsheng1)CAO Weijie<sup>1)
1)Department of Hematology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052;2)Department of Nephrology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052
关键词:
多发性骨髓瘤 肾损害 轻链蛋白
Keywords:
multiple myeloma renal impairment light chain protein
分类号:
R733.3
DOI:
10.13705/j.issn.1671-6825.2018.09.136
摘要:
目的:分析多发性骨髓瘤(MM)合并肾损害患者的临床及病理特征,以提高诊断和治疗水平。方法:回顾性分析MM合并肾损害的22例患者的临床及病理资料。结果与结论:MM合并肾损害的临床症候群以肾功能不全最为常见(72.7%),常伴有高尿酸血症,同时尿蛋白检出率高,但大量蛋白尿发生率较低。MM合并肾损害患者肾脏病理表现多样,不同病理类型具有各自的临床特点,与淀粉样变性患者相比,非淀粉样变性患者贫血相对较重,肌酐升高程度更明显,尿本周蛋白阳性率高(P<0.05)。血免疫电泳轻链阳性率86.4%(19/22),尿中轻链阳性率为75.0%(9/12),均以λ轻链为主。
Abstract:
Aim:To analyze the clinical and pathological features of patients with multiple myeloma(MM)complicated with renal impairment,so as to improve diagnosis and treatment levels.Methods:The clinical and pathological data of 22 patients who were diagnosed MM with renal impairment were retrospectively analyzed.Results and Conclusion:The most common clinical syndrome of MM with renal impairment was renal insufficiency(72.7%), often accompanied with hyperuricemia, and the detection rate of urinary protein was high, but the incidence of proteinuria was low. Renal pathological manifestations of MM patients with renal impairment were diverse. Different pathological types had their own clinical features. Compared with patients with amyloidosis, patients with non-amyloidosis had relatively severe anemia, and creatinine increased more significantly,and the positive rate of Bence-Jones protein in urine was high(P<0.05). The blood immunoelectrophoresis light chain positive rate was 86.4%(19/22), and the urinary light chain positive rate was 75.0%(9/12), among which were mainly λ light chain.

参考文献/References:

[1] SHI H,CHEN Z,XIE J,et al.The prevalence and management of multiple myeloma-induced kidney disease in China[J].Kidney Dis(Basel),2016,1(4):235
[2] ESLICK R,TALAULIKAR D.Multiple myeloma: from diagnosis to treatment[J].Aust Fam Physician,2013,42(10):684
[3] 潘志兰,张永梅,张志敏,等.多发性骨髓瘤肾病的临床特点及其相关因素分析[J].临床合理用药杂志,2014,7(8B):6
[4] HAYNES RJ, READ S, COLLINS GP, et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre[J]. Nephrol Dial Transplant, 2010, 25(2):419
[5] KNUDSEN LM,HJORTH M,HIPPE E. Renal failure in multiple myeloma: reversibility and impact on the prognosis[J]. Eur J Haematol, 2010, 65(3):175
[6] 李富浩,贺红光,唐盛,等.合并肾损害的多发性骨髓瘤患者临床特点及预后[J].广西医学,2017,39(11):1623
[7] 张津京,李艳.初诊多发性骨髓瘤合并肾功能不全患者的临床特点和疗效分析[J].中国医科大学学报,2016,45(6):494
[8] MEHTAT ÜNLÜ S, ÖZSAN H, SARIOGLU S. The scope of kidney affection in monoclonal gammopathies at all levels of clinical significance[J]. Turk J Hematol, 2017,34(4):282
[9] RAJKUMAR SV, DIMOPOULOS MA, PALUMBO A,et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma [J]. Lancet Oncol, 2014, 15(12):e538
[10]杨秀,王庆文,王金泉,等.多发性骨髓瘤肾损害尿蛋白性质的分析及临床意义[J].医学研究生学报,2007,20(3):290
[11]HUTCHISON CA,BATUMAN V,BEHRENS J,et al.The pathogenesis and diagnosis of acute kidney injury in multiple myeloma[J].Nat Rev Nephrol,2011,8(1):43
[12]HEHER EC,RENNKE HG,LAUBACH JP,et al. Kidney disease and multiple myeloma[J].Clin J Am Soc Nephrol,2013,8(11): 2007
[13]GOLDSCHMIDT H,LANNERT H,BOMMER J,et al. Multiple myeloma and renal failure[J]. Nephrol Dial Transplant, 2000, 15(3):301
[14]黄湘华,蒋松,史明君,等.原发性系统性淀粉样变性的预后及危险因素分析[J].肾脏病与透析肾移植杂志,2012,21(4):304
[15]杨晓青,张秀辉,胡章学.淀粉样变性肾病的临床病理研究[J].临床与实验病理学杂志,2006,22(2):165
[16]KYLE RA,GERTZ MA,WITZIG TE,et al. Review of 1027 patients with newly diagnosed multiple mueloma[J]. Mayo Clin Proc,2003,78(1):21
[17]王成玉,王涵,廖蕴华,等.多发性骨髓瘤合并肾损害患者的临床特征及相关危险因素分析[J].中国全科医学,2011,14(10A):3235
[18]王建文,彭佑铭,魏佳莉,等.多发性骨髓瘤44例肾损害临床特征分析[J].医学临床研究,2005,22(11):1537

相似文献/References:

[1]胡杰英),蒋东霞),范瑞华),等.多发性骨髓瘤14例间期荧光原位杂交分析[J].郑州大学学报(医学版),2010,(04):659.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(04):659.
[2]革化民,崔静,刘保平#,等.骨显像和CT诊断多发性骨髓瘤骨质破坏的比较革化民[J].郑州大学学报(医学版),2010,(06):1031.
[3]戴豫苏,孙 玲#,孙 慧,等.硼替佐米联合地塞米松及沙利度胺治疗多发性骨髓瘤的临床疗效戴豫苏,孙 玲,孙 慧,陈绍倩,刘林湘,[J].郑州大学学报(医学版),2016,(04):554.
[4]刘延方,白俊俊,王树娟,等.伴13q14缺失的初诊多发性骨髓瘤患者的临床特征和治疗反应[J].郑州大学学报(医学版),2019,(01):110.[doi:10.13705/j.issn.1671-6825.2018.07.123]
 LIU Yanfang,BAI Junjun,WANG Shujuan,et al.Clinical features and response to therapies in de novo multiple myeloma patients with 13q14 deletion[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(04):110.[doi:10.13705/j.issn.1671-6825.2018.07.123]

备注/Memo

备注/Memo:
【基金项目】河南省卫计委科技攻关项目(201403034); 河南省医学科技攻关计划省部共建项目(SBGJ2018035)
【作者简介】王芳,通信作者,女,1973年1月生,硕士,副主任医师,研究方向:多发性骨髓瘤,E-mail:wfhappy126@126.com
更新日期/Last Update: 2019-07-20